This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
AML に準じた治療を行っていたが,Down 症児は非 Down 症児に比べ治療反応性が良好である一方,骨髄抑制をはじめとする治療関連毒性が強いことが問題であった。それを踏まえて近年では,非 Down 症児の AML 治療を減弱した研究が行われ,3 年 EFSが 75〜90%と治療成績の向上が得られている51−53)。
一方,本邦では,1987〜97 年の AT−DS 研究,2000〜04 年の AML99 Down プロトコール研究と Down 症候群の AML に特化した治療研究が行われ,3 年 EFS が 80〜85%と欧米に遜色ない良好な成績をあげている54,55)。
7CQ
急性骨髄性白血病
AML
文献検索と文献採択 * 55
Ⅳ文献検索と文献採択▶ CQ1 小児 AML の治療方針の決定に必要な分類と検査は何か
本項目は関連キーワードが多岐に及び,システマティックな文献検索方法は適用できない
ため省略した。
▶ CQ2 小児 AML の標準的寛解導入治療は何か▶ CQ3 小児 AML の寛解後の標準的治療は何か
【文献】 1) Arber DA, et al : Acute myeloid leukemia with recurrent geneteic abnormalities. WHO
Classification of Tumors of Haematopoietic and Lymphoid Tissues, 4th ed, IARC, 2007, p109−148. 2) Meshinchi S, Arceci RJ : Prognostic factors and risk−based therapy in pediatric acute myeloid
leukemia. Oncologist 12 : 341−355, 2007. (構造化抄録) 3) Grimwade D, Walker H, Oliver F, et al : The importance of diagnostic cytogenetics on outcome
in AML : analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92 : 2322−2333, 1998. (Ⅳ)(構造化抄録)
4) Wheatley K, Burnett AK, Goldstone AH, et al : A simple, robust, validated and highly predictive index for the determination of risk−directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. Br J Haematol 107 : 69−79, 1999. (Ⅳ)(構造化抄録)
5) Creutzig U, Zimmermann M , Ritter J, et al : Definition of a standard−risk group in children with AML. Br J Haematol 104 : 630−639, 1999.
6) 多和昭雄:急性骨髄性白血病の治療.日小血会誌 23 : 257−265, 2009. 7) Kaspers GJ, Zwaan CM : Pediatric acute myeloid leukemia : towards high−quality cure of all
patients. Haematologica 92 : 1519−1532, 2007. (構造化抄録) 8) Tsukimoto I, Tawa A, Horibe K, et al : Risk−stratified therapy and the intensive use of
cytarabine improves the outcome in childhood acute myeloid leukemia : the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol 27 : 4007−4013, 2009. (Ⅲ)(構造化抄録)
9) Meshinchi S, Alonzo TA, Stirewalt DL, et al : Clinical implications of FLT3 mutations in pediatric AML. Blood 108 : 3654−3661, 2006. (Ⅳ)
10) Shimada A, Taki T, Tabuchi K, et al : Tandem duplications of MLL and FLT3 are correlated with poor prognoses in pediatric acute myeloid leukemia : a study of the Japanese Childhood AML Cooperative Study Group. Pediatr Blood Cancer 50 : 264−269, 2008. (Ⅳ)
11) Balgobind BV, Raimondi SC, Harbott J, et al : Novel prognostic subgroups in childhood 11q23/MLL−rearranged acute myeloid leukemia : results of an international retrospective study. Blood 114 : 2489−2496, 2009.
12) Vormoor J, Boos J, Stahnke K, et al : Therapy of childhood acute myelogenous leukemias. Ann Hematol 73 : 11−24, 1996. (構造化抄録)
13) Kaspers GJ, Creutzig U : Pediatric acute myeloid leukemia : international progress and future directions. Leukemia 19 : 2025−2029, 2005. (構造化抄録)
14) Stevens RF, Hann IM, Wheatley K, et al : Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia : results of the United Kingdom Medical Research Council’s 10th AML trial. Br J Haematol 101 : 130−140, 1998. (Ⅱ)
15) Creutzig U, Zimmermann M , Lehrnbecher T, et al : Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony−stimulating factor in children and adolescents with acute myeloid leukemia : results of AML−BFM98. J Clin Oncol 24 : 4499−4506, 2006. (Ⅱ)
16) Hann IM, Stevens RF, Goldstone AH, et al : Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council’s 10th AML trial(MRC AML 10). Blood 89 : 2311−2318, 1997.(Ⅱ)
17) Creutzig U, Ritter J, Zimmermann M, et al : Idarubicin improves blast cell clearance during induction therapy in children with AML : results of study AML−BFM93. Leukemia 15 : 348−354, 2001. (Ⅱ)
18) O’Brien TA, Russell SJ, Vowels MR, et al : Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children’s Cancer Study Group. Blood 100 : 2708−2716, 2002. (Ⅲ)
19) Lange BJ, Smith FO, Feusner J, et al : Outcomes in CCG−2961, a Children’s Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia : a report fron the Children’s Oncology Group. Blood 111 : 1044−1053, 2008. (Ⅱ)
Pharmacother 10 : 57−79, 2009. (Ⅳ) 22) Rubnitz JE : Childhood acute myeloid leukemia. Curr Treat Options Oncol 9 : 95−105, 2008. (Ⅳ) 23) Rubnitz JE, Gibson B, Smith FO : Acute myeloid leukemia. Pediatr Clin North Am 55 : 21−51,
2008. (Ⅳ) 24) Gibson BE, Wheatley K, Hann IM, et al : Treatment strategy and long−term results in paediatric
文献 * 57
急性骨髄性白血病
AML
patients treated in consecutive UK AML trials. Leukemia 19 : 2130−2138, 2005. 25) Bloomfield CD, Lawrence D, Byrd JC, et al : Frequency of prolonged remission duration after
high−dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58 : 4173−4179, 1998. (Ⅲ)
26) Byrd JC, Dodge RK, Carroll A, et al : Patients with t(8 ; 21)(q22 ; q22)and acute myeloid leukemia have superior failure−free and overall survival when repetitive cycles of high−dose cytarabine are administered. J Clin Oncol 17 : 3767−3775, 1999. (Ⅱ)
28) Tomizawa D, Tabuchi K, Kinoshita A, et al : Repetitive cycles of high−dose cytarabine are effective for childhood acute myeloid leukemia : long−term outcome of the children with AML treated on two consecutive trials of Tokyo Children’s Cancer Study Group. Pediatr Blood Cancer 49 : 127−132, 2007.
29) Perel Y, Auvrignon A, Leblanc T, et al : Treatment of childhood acute myeloblastic leukemia : dose intensification improves outcome and maintenance therapy is of no benefit─multicenter studies of the French LAME(Leucémie Aiguë Myéloblastique Enfant)Cooperative Group. Leukemia 19 : 2082−2089, 2005. (Ⅱ)
30) Perel Y, Auvrignon A, Leblanc T, et al : Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia : results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde Enfant. J Clin Oncol 20 : 2774−2782, 2002. (Ⅱ)(構造化抄録)
31) Creutzig U, Zimmermann M, Ritter J, et al : Treatment strategies and long−term results in paediatric patients treated in four consecutive AML−BFM trials. Leukemia 19 : 2030−2042, 2005.
32) Yamada M, Matsuo K, Emi N, et al : Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission : a metaanalysis. Cancer 103 : 1652−1658, 2005. (Ⅰ)
33) Basara N, Schulze A, Wedding U, et al : Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia−free survival compared with conventional chemotherapy in high−risk acute myeloid leukaemia patients in first complete remission. Leukemia 23 : 635−640, 2009. (Ⅲ)
34) 日本造血細胞移植学会:平成 21 年度 全国調査報告書.2010. 35) Michel G, Rocha V, Chevret S, et al : Unrelated cord blood transplantation for childhood acute
myeloid leukemia : a Eurocord Group analysis. Blood 102 : 4290−4297, 2003. 36) 日本造血細胞移植学会:造血幹細胞移植の適応ガイドライン(JSHCT monograph Vol.6, 2002). http://www.jshct.com/guideline/pdf/2002.pdf 37) Aladjidi N, Auvrignon A, Leblanc T, et al : Outcome in children with relapsed acute myeloid
leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant(LAME)89/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol 21 : 4377−4385, 2003. (Ⅲ)
38) Rubnitz JE, Razzouk BI, Lensing S, et al : Prognostic factors and outcome of recurrence in childhood acute myeloid leukemias. Cancer 109 : 157−163, 2007. (Ⅲ)
39) Nemecek ER, Gooley TA, Woolfrey AE, et a l : Outcome of a l logeneic bone marrow transplantation for children with advanced acute myeloid leukemia. Bone Marrow Transplant 34 : 799−806, 2004. (Ⅲ)
40) Abrahamsson J, Clausen N, Gustafsson G, et al : Improved outcome after relapse in children with acute myeloid leukaemia. Br J Haematol 136 : 229−236, 2006. (Ⅲ)
41) Shenoy S, Smith FO : Hematopoietic stem cell transplantation for childhood malignancies of myeloid origin. Bone Marrow Transplant 41 : 141−148, 2008.
42) Bunin NJ, Davies SM, Aplenc R, et al : Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy. J Clin Oncol 26 : 4326−4332, 2008. (Ⅲ)
43) Sanz MA, Grimwade D, Tallman MS, et al : Management of acute promyelocytic leukemia : recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113 : 1875−1891, 2009. (Ⅱ)
44) 高橋浩之:小児急性前骨髄球性白血病の治療.日小血会誌 23 : 266−273, 2009. (Ⅱ) 45) de la Serna J, Montesinos P, Vellenga E, et al : Causes and prognostic factors of remission
induction failure in patients with acute promyelocytic leukemia treated with all−trans retinoic
58* 急性骨髄性白血病 AML
acid and idarubicin. Blood 111 : 3395−3402, 2008. (Ⅱ) 46) Montesinos P, Bergua JM, Vellenga E, et al : Differentiation syndrome in patients with acute
promyelocytic leukemia treated with all−trans retinoic acid and anthracycline chemotherapy : characteristics, outcome, and prognostic factors. Blood 113 : 775−783, 2009. (Ⅱ)
47) de Botton S, Coiteux V, Chevret S, et al : Outcome of childhood acute promyelocytic leukemia with all−trans retinoic acid and chemotherapy. J Clin Oncol 22 : 1404−1412, 2004. (Ⅲ)
48) Testi AM, Biondi A, Lo Coco F, et al : GIMEMA−AIEOP AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia(APL)in children. Blood 106 : 447−453, 2005. (Ⅲ)(構造化抄録)
49) Ortega JJ, Madero L, Martín G, et al : Treatment with all−trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia : A multicenter study by the PETHEMA group. J Clin Oncol 23 : 7632−7640, 2005. (Ⅲ)
50) Imaizumi M, Tawa A, Hanada R, et al : Prospective study of a therapeutic regimen with all−trans retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia : the Japanese childhood acute myeloid leukaemia cooperative study. Br J Haematol 152 : 89−98, 2011. (Ⅲ)
51) Creutzig U, Reinhardt D, Diekamp S, et al : AML patients with Down syndrome have a high cure rate with AML−BFM therapy with reduced dose intensity. Leukemia 19 : 1355−1360, 2005.(Ⅲ)(構造化抄録)
52) Gamis AS, Woods WG, Alonzo TA, et al : Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia : a report from the Children’s Cancer Group Study 2891. J Clin Oncol 21 : 3415−3422, 2003. (Ⅳ)(構造化抄録)
53) Abildgaard L, Ellebaek E, Gustafsson G, et al : Optimal treatment intensity in children with Down syndrome and myeloid leukaemia : data from 56 children treated on NOPHO−AML protocols and review of the literature. Ann Haematol 85 : 275−280, 2006. (Ⅳ)(構造化抄録)
54) Kojima S, Sako M, Kato K, et al : An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down’s syndrome. Leukemia 14 : 786−791, 2000. (Ⅲ)(構造化抄録)
55) Kudo K, Kojima S, Tabuchi K, et al : Prospective study of a pirarubicin, intermediate−dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia : the Japanese Childhood AML Cooperative Study Group. J Clin Oncol 25 : 5442−5447, 2007. (Ⅲ)(構造化抄録)